thyroid cancer and semaglutide no incidence to date of semaglutide causing any kind of thyroid cancer - Mounjarothyroid cancerpercentage may increase the risk that you will develop thyroid tumors Understanding the Nuances of Thyroid Cancer and Semaglutide

Has anyone gotthyroid cancerfrom Wegovy The emergence of semaglutide, a popular glucagon-like peptide-1 (GLP-1) receptor agonist marketed under brand names such as Ozempic and Wegovy, has brought significant advancements in managing type 2 diabetes and obesity.作者：M Munshi·2025—Available animal research shows that the use ofsemaglutide can increase the risk of developing thyroid C-cell tumours[1]. Based on these ... However, discussions surrounding its use have also raised questions about its potential link to thyroid cancer. This article aims to provide a comprehensive overview of the current understanding regarding thyroid cancer and semaglutide, drawing upon available research and expert insights to address patient concerns and inform clinical perspectives.

Investigating the Potential Link: Animal Studies vs.作者：B Pasternak·2024·被引用次数：122—GLP1 receptor agonist use was not associated with a substantially increased risk ofthyroid cancerover a mean follow-up of 3.9 years. Human Data

Early research, particularly in animal models, suggested a potential link between GLP-1 receptor agonists, including semaglutide, and an increased risk of developing thyroid C-cell tumors. Specifically, some animal studies indicated that semaglutide can increase the risk of developing thyroid C-cell tumours. This finding led to a "boxed warning," also known as a black box warning, on some GLP-1 RA product information. This warning alerts healthcare professionals and patients to the possibility that semaglutide has a black box warning about a possible link to a rare thyroid cancer called medullary thyroid cancer (MTC)Semaglutide and cancer: A systematic review and meta .... Consequently, individuals with a personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2) have historically been advised against using these medications, as GLP-1 receptor agonists, including liraglutide, dulaglutide, exenatide, and semaglutide, have been contraindicated by the U.GLP-1 Medications and Thyroid Cancer RiskS. Food and Drug Administration in such casesGLP-1 Receptor Agonists Not Associated With Increased ....

However, it is crucial to differentiate between animal findings and human clinical outcomes.Rapid Progression of Papillary Thyroid Carcinoma ... The relevance of these animal-based concerns to humans has been a subject of extensive investigation. Emerging human data and comprehensive analyses have begun to paint a clearer picture.2025年4月1日—Semaglutide has a black box warning about a possible link to a rare thyroid cancercalled medullary thyroid cancer (MTC). You may also see this ... Several large-scale human studies and systematic reviews have investigated the association between semaglutide use and thyroid cancer作者：CVI Feier·2024·被引用次数：79—The incidence of thyroid cancer in semaglutide-treated patients wasless than 1%, suggesting no significant risk. Adverse events were .... These studies consistently report that the incidence of thyroid cancer in patients treated with semaglutide is notably low. For instance, some assessments indicate an incidence of less than 1%, suggesting no significant risk.

Current Research and Clinical Findings on Semaglutide and Thyroid Cancer

A growing body of evidence supports the safety of semaglutide concerning thyroid cancer risk in humans. For example, a significant study published in The Journal of Clinical Endocrinology & Metabolism revealed that semaglutide does not promote thyroid cancer; instead, it may have a protective effect. This groundbreaking study challenges earlier fears and suggests a more nuanced understanding of the drug's impact.Papillary Thyroid Carcinoma Following Semaglutide Therapy ...

Further research, including a systematic review and meta-analysis of semaglutide and cancer, concluded that thyroid cancer not increased with semaglutide. Similar findings have been reported in other large human studies where neither semaglutide nor tirzepatide have been proven to increase the risk of thyroid cancerSemaglutide for Weight Loss in Patients with a Family .... The totality of available human data continues to support the safety of semaglutide with respect to thyroid cancer risk.2026年1月7日—Use of liraglutide orsemaglutidetherapy does not increase risk forthyroid canceramong patients with type 2 diabetes or obesity.

It is important to note that while the overall risk appears low, rare cases of papillary thyroid carcinoma (PTC) have been reported following semaglutide therapy. For instance, a case presentation described a patient experiencing rapidly progressive PTC shortly after initiating semaglutide for weight loss, indicating that while exceedingly rare, such occurrences are documented. However, it is often challenging to establish a definitive causal link due to confounding factors and the inherent long latency period of many cancersDo Semaglutide or Tirzepatide cause thyroid cancer?.

Understanding the Mechanisms and the Role of GLP-1 Receptors

The scientific understanding of how GLP-1 receptor agonists interact with thyroid cells is evolving. Some research suggests that semaglutide reprograms macrophages via the GLP-1R/PPARG/ACSL1 pathway to suppress papillary thyroid carcinoma growth. This indicates a potential biological mechanism that could counteract, rather than promote, tumor development.Stillit isn't advised. Regardless it's between you and your doctor. So you do you but people should be aware of the risk of it triggering ...

Despite the reassuring data, regulatory bodies like the U.S. Food and Drug Administration (FDA) maintain vigilance. The FDA has placed boxed warnings on semaglutide-containing products due to the theoretical risk of thyroid tumors, including medullary thyroid carcinoma (MTC)Semaglutide and cancer: A systematic review and meta- .... This approach emphasizes the importance of continued monitoring and patient selection.

Factors to Consider for Patients and Clinicians

When considering semaglutide therapy, several factors are paramount:

* Personal and Family History: Patients with a personal or family history of thyroid cancer, particularly MTC, or MEN 2, should have a thorough discussion with their healthcare provider. While recent data suggests a low risk, individualized risk assessment is crucial.Rapid Progression of Papillary Thyroid Carcinoma ...

* Monitoring: Regular follow-up with healthcare providers is essential for all patients using semaglutide. Any new or persistent symptoms related to the thyroid, such as a lump in the neck, hoarseness, or difficulty swallowing, should be promptly reported.

* Risk vsRisk of Thyroid Tumors With GLP-1 Receptor Agonists. Benefit Analysis: For many individuals with type 2 diabetes or obesity, the significant benefits of semaglutide in improving glycemic control, promoting weight loss, and reducing cardiovascular risk may outweigh the theoretical or low-identified risks of thyroid cancer. This requires a personalized risk-benefit analysis conducted with a qualified healthcare professional.Papillary Thyroid Carcinoma Following Semaglutide Therapy ...

* Ongoing Research: The scientific community continues to investigate the long-term effects of semaglutide and other GLP-1 receptor agonists.2024年9月5日—While researchers have foundno incidence to date of semaglutide causing any kind of thyroid cancerin humans, the earliest laboratory research ... Keeping abreast of the latest research is vital for both patients and clinicians.

Conclusion

The relationship between thyroid cancer and semaglutide is complex and has been a subject of considerable scientific inquiry.作者：B Pasternak·2024·被引用次数：122—GLP1 receptor agonist use was not associated with a substantially increased risk ofthyroid cancerover a mean follow-up of 3.9 years. While early animal studies raised concerns prompting warnings, extensive human data and systematic reviews have largely indicated that semaglutide does not increase the risk of thyroid cancer. The incidence of thyroid tumors in patients using semaglutide appears to be minimal, and in some cases, it is not associated with a substantially increased risk of thyroid cancer. However, given the existence of a black box warning and the occurrence of rare cases, ongoing vigilance, informed patient-physician communication, and continued research are essential to ensure the safe and effective use of semaglutide for its intended therapeutic purposes. Ultimately, the decision to use semaglutide should be made in consultation with a healthcare provider, considering the individual patient's medical history, potential risks, and therapeutic benefits.